SGMOQ on OTC
SANGAMO THERAPEUTICS, INC
In its 2026 annual report the company says: “We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Our neurology development is focused on two innovative areas: (i) development of epigenetic regulation therapies to treat serious neurological diseases and (ii) development of novel engineered adeno-associated virus, or AAV, capsids to deliver our therapies to the intended neurological targets.”4 It is headquartered in Richmond, California.1 Its shares trade on OTC under the symbol SGMOQ.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Kymera Therapeutics, Voyager Therapeutics (United States) or Editas Medicine, or pick any stock.
- TickerSGMOQ on OTC1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersRichmond, California1
- Incorporated inDE2
- Business address501 Canal Blvd., Richmond, Ca 940842
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development99¢$112.7M
- Income tax1¢$568.0K
Out of $39.6M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $39.6M | $57.8M |
| Research and development | $112.7M | $111.5M |
| General and administrative | $34.9M | $44.7M |
| Impairment of long-lived assets | $13.2M | $5.5M |
| Total operating expenses | $160.8M | $161.8M |
| Loss from operations | -$121.2M | -$104.0M |
| Interest income | $1.3M | $1.5M |
| Other (expense) income, net | -$3.6M | $4.3M |
| Loss before income taxes | -$123.5M | -$98.1M |
| Income tax benefit | -$568.0K | -$167.0K |
| Net loss | -$122.9M | -$97.9M |
| Basic net loss per share (in dollars per share) | -$0.44 | -$0.49 |
| Diluted net loss per share (in dollars per share) | -$0.44 | -$0.49 |
| Shares used in computing basic net loss per share (in shares) | 280.2M shares | 201.7M shares |
| Shares used in computing diluted net loss per share (in shares) | 280.2M shares | 201.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $20.9M | $41.9M | |||
| Accounts receivable | $371.0K | $526.0K | |||
| Refundable research income tax credits | $10.1M | $4.1M | |||
| Prepaid expenses and other current assets | $4.4M | $5.2M | |||
| Total current assets | $35.8M | $51.7M | |||
| Property and equipment, net | $11.0M | $17.9M | |||
| Operating lease right-of-use assets | $3.1M | $16.9M | |||
| Refundable research income tax credits, non-current | $8.9M | $12.8M | |||
| Other non-current assets | $871.0K | $879.0K | |||
| Restricted cash | $0 | $1.5M | |||
| Total assets | $59.7M | $101.6M | |||
| Accounts payable | $14.4M | $15.5M | |||
| Accrued compensation and employee benefits | $17.7M | $14.6M | |||
| Other accrued liabilities | $9.4M | $8.2M | |||
| Deferred revenues | $899.0K | $7.6M | |||
| Total current liabilities | $42.5M | $45.8M | |||
| Deferred revenues, non-current | $5.9M | $5.9M | |||
| Long-term portion of lease liabilities | $25.1M | $26.3M | |||
| Other non-current liabilities | $580.0K | $933.0K | |||
| Total liabilities | $74.0M | $78.9M | |||
| Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding | $0 | $0 | |||
| Common stock, $0.01 par value; 960,000,000 shares authorized; 350,688,142 and 212,837,679 shares issued and outstanding at December 31, 2025 and 2024, respectively | $3.5M | $2.1M | |||
| Additional paid-in capital | $1.6B | $1.5B | |||
| Accumulated deficit | -$1.6B | -$1.5B | |||
| Accumulated other comprehensive loss | -$1.5M | -$7.5M | |||
| Total stockholders equity (deficit) | -$14.3M | $22.8M | $82.9M | ||
| Total liabilities and stockholders equity (deficit) | $59.7M | $101.6M | |||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |||
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |||
| Common stock, shares authorized (in shares) | 960.0M shares | 960.0M shares | 960.0M shares | 640.0M shares | |
| Common stock, shares issued (in shares) | 350.7M shares | 212.8M shares | |||
| Beginning balance (in shares) | 350.7M shares | 212.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $20.9M | $41.9M | |||
| Accounts receivable | $371.0K | $526.0K | |||
| Refundable research income tax credits | $10.1M | $4.1M | |||
| Prepaid expenses and other current assets | $4.4M | $5.2M | |||
| Total current assets | $35.8M | $51.7M | |||
| Property and equipment, net | $11.0M | $17.9M | |||
| Operating lease right-of-use assets | $3.1M | $16.9M | |||
| Refundable research income tax credits, non-current | $8.9M | $12.8M | |||
| Other non-current assets | $871.0K | $879.0K | |||
| Restricted cash | $0 | $1.5M | |||
| Total assets | $59.7M | $101.6M | |||
| Accounts payable | $14.4M | $15.5M | |||
| Accrued compensation and employee benefits | $17.7M | $14.6M | |||
| Other accrued liabilities | $9.4M | $8.2M | |||
| Deferred revenues | $899.0K | $7.6M | |||
| Total current liabilities | $42.5M | $45.8M | |||
| Deferred revenues, non-current | $5.9M | $5.9M | |||
| Long-term portion of lease liabilities | $25.1M | $26.3M | |||
| Other non-current liabilities | $580.0K | $933.0K | |||
| Total liabilities | $74.0M | $78.9M | |||
| Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding | $0 | $0 | |||
| Common stock, $0.01 par value; 960,000,000 shares authorized; 350,688,142 and 212,837,679 shares issued and outstanding at December 31, 2025 and 2024, respectively | $3.5M | $2.1M | |||
| Additional paid-in capital | $1.6B | $1.5B | |||
| Accumulated deficit | -$1.6B | -$1.5B | |||
| Accumulated other comprehensive loss | -$1.5M | -$7.5M | |||
| Total stockholders equity (deficit) | -$14.3M | $22.8M | $82.9M | ||
| Total liabilities and stockholders equity (deficit) | $59.7M | $101.6M | |||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | |||
| Preferred stock, shares authorized (in shares) | 5.0M shares | 5.0M shares | |||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |||
| Common stock, shares authorized (in shares) | 960.0M shares | 960.0M shares | 960.0M shares | 640.0M shares | |
| Common stock, shares issued (in shares) | 350.7M shares | 212.8M shares | |||
| Beginning balance (in shares) | 350.7M shares | 212.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$122.9M | -$97.9M |
| Impairment of long-lived assets | $13.2M | $5.5M |
| Depreciation and amortization | $4.0M | $5.1M |
| Amortization of operating lease right-of-use assets | $3.6M | $4.3M |
| Stock-based compensation | $9.1M | $12.4M |
| Gain on sale of assets classified as held for sale | $0 | -$1.0M |
| Other | $32.0K | $57.0K |
| Accounts receivable | $155.0K | $397.0K |
| Refundable research income tax credits | $0 | $556.0K |
| Prepaid expenses and other assets | $830.0K | $4.4M |
| Accounts payable and other accrued liabilities | $2.8M | -$14.2M |
| Accrued compensation and employee benefits | $3.1M | $5.7M |
| Deferred revenues | -$6.7M | $13.4M |
| Lease liabilities | -$4.0M | -$5.6M |
| Other non-current liabilities | -$352.0K | -$255.0K |
| Net cash used in operating activities | -$97.2M | -$67.1M |
| Maturities of marketable securities | $0 | $1.1M |
| Proceeds from sale of marketable securities | $0 | $34.7M |
| Proceeds from sale of assets classified as held for sale | $0 | $2.0M |
| Purchases of property and equipment | -$102.0K | -$267.0K |
| Net cash (used in) provided by investing activities | -$102.0K | $37.5M |
| Proceeds from at-the-market offering, net of offering expenses | $52.2M | $7.1M |
| Proceeds from issuance of common stock, net of offering expenses | $21.5M | $21.9M |
| Taxes paid related to net share settlement of equity awards | -$3.3M | -$904.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $344.0K | $290.0K |
| Net cash provided by financing activities | $70.7M | $28.4M |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | $4.1M | -$2.0M |
| Net decrease in cash, cash equivalents and restricted cash | -$22.5M | -$3.3M |
| Property and equipment included in unpaid liabilities | $74.0K | $236.0K |
No quarter-by-quarter statement was filed.
Corporate structure
SANGAMO THERAPEUTICS, INC sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of SANGAMO THERAPEUTICS, INC
- ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on SANGAMO THERAPEUTICS, INC, latest Aug 14, 2026 (2 filings since May 15, 2026)
- WASATCH ADVISORS LP Filed SCHEDULE 13G/A on SANGAMO THERAPEUTICS, INC, latest Nov 12, 2025 (8 filings since Feb 11, 2022)
- VANGUARD GROUP INC Filed SC 13G/A on SANGAMO THERAPEUTICS, INC, latest Nov 12, 2024 (5 filings since Feb 10, 2022)
- Biogen Filed SC 13G/A on SANGAMO THERAPEUTICS, INC, latest Aug 16, 2024 (2 filings since Feb 12, 2024)
- BlackRock Filed SC 13G/A on SANGAMO THERAPEUTICS, INC, latest Jul 8, 2024 (4 filings since Feb 1, 2022)
- State Street Corporation Filed SC 13G/A on SANGAMO THERAPEUTICS, INC, latest Jan 22, 2024 (2 filings since Feb 7, 2023)
- SANGAMO THERAPEUTICS, INC Richmond, California
- Sangamo Therapeutics France S.A.S. Subsidiary · France
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What SANGAMO THERAPEUTICS, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $53.3M5 Dec 31, 2025 | $57.7M5 Dec 31, 2024 | −7.7% |
| Accumulated depreciation | $42.2M5 Dec 31, 2025 | $39.8M5 Dec 31, 2024 | +6.0% |
| Property and equipment, net | $11.0M5 Dec 31, 2025 | $17.9M5 Dec 31, 2024 | −38.3% |
| Operating-lease assets (leased space) | $3.1M5 Dec 31, 2025 | $16.9M5 Dec 31, 2024 | −81.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $20.9M5 Dec 31, 2025 | $41.9M5 Dec 31, 2024 | −50.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $09 Dec 31, 2024 | $09 Dec 31, 2023 | |
| Intangible assets, net (excluding goodwill) | $09 Dec 31, 2024 | $09 Dec 31, 2023 |
Properties, in its own words
Our corporate headquarters occupies approximately 59,485 square feet of research and office space, pursuant to a lease that expires in August 2031, and we occupy approximately 7,700 square feet of office space, pursuant to a lease that expires in August 2026, in Richmond, California. We also lease approximately 103,089 square feet of office space and a research and
development laboratory facility in Brisbane, California, pursuant to a lease that expires in May 2029. We believe that our facilities are currently adequate to meet our needs.
Item 2 of the 10-K filed Mar 30, 2026.4
Leadership
Who has led SANGAMO THERAPEUTICS, INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2010201520202025
- Chief executive officerSandy Macrae Jun 6, 2016 to now14
- Chief executive officerEdward O. Lanphier Ii. Jan 31, 2006 to Dec 15, 201515
- PresidentSandy Macrae Jun 6, 2016 to now14
- PresidentEdward O. Lanphier Ii. Jan 31, 2006 to Dec 15, 201515
- Chief financial officerPrathyusha Duraibabu Jun 14, 2021 to now16
- Chief financial officerStephane Boissel Aug 14, 2019 to Aug 14, 201917
- Chief financial officerKathy Yi Mar 2, 2017 to May 17, 201918
- Chief financial officerHenry Ward Wolff Dec 5, 2007 to Dec 14, 201619
Board members and other officers (43)
- Principal Accounting OfficerNikunj Jain Oct 9, 2025 to now20
- Head of Research & TechnologyGregory D. Davis Oct 28, 2024 to now21
- VP, Head of ResearchAmy Pooler Nov 28, 2023 to Aug 27, 202422
- SVP-Chief Development OfficerNathalie Dubois-Stringfellow Sep 19, 2022 to now23
- SVP, Head of DevelopmentRobert J. Schott Feb 10, 2021 to Mar 1, 202224
- SVP, Chief Scientific OfficerJason D. Fontenot Mar 19, 2021 to Nov 28, 202325
- SVP, Gen. Counsel & SecretaryScott B. Willoughby Aug 9, 2021 to now26
- EVP, Research and DevelopmentAdrian Woolfson Jan 23, 2019 to Feb 27, 202027
- VP, Principal Acct. OfficerPrathyusha Duraibabu Jun 18, 2019 to now28
- EVP, Technical OperationsRolf Andrew Ramelmeier Sep 26, 2019 to May 30, 202329
- EVP, Corporate StrategyStephane Boissel Oct 4, 2018 to Jul 31, 202030
- Senior VP & CBOCurt A. Herberts Iii. Dec 2, 2016 to Apr 17, 201831
- Senior VP & CMOEdward R. Conner Dec 2, 2016 to Jan 28, 201932
- Executive Vice President, R&DGeoffrey Nichol Jul 11, 2011 to Dec 15, 201533
- Sr. Director Finance & AdminGreg Zante Jun 5, 2006 to Mar 12, 200834
- Vice President, ResearchPhilip D. Gregory Jun 6, 2006 to Jun 3, 201535
- Pres & Chief Ex OfficerEdward O. Lanphier Ii. Aug 31, 2006 to Aug 19, 200836
- VP, Therapeutic Dev. & CMODale G. Ando Dec 13, 2006 to Dec 15, 201537
- Senior VP, Bus. Dev.David G. Ichikawa Dec 13, 2006 to Dec 12, 201138
- Board memberCourtney Beers Dec 19, 2022 to now39
- Board memberMargaret A. Horn Dec 19, 2022 to now40
- Board memberJohn Markels Feb 13, 2020 to now41
- Board memberKenneth Hillan Sep 11, 2020 to now42
- Board memberJames R. Meyers Nov 26, 2019 to now43
- Board memberSandy Macrae Jan 31, 2018 to now44
- Board memberKaren L. Smith Jun 28, 2018 to now45
- Board memberJoseph S. Zakrzewski Jun 29, 2017 to Mar 1, 202246
- Board memberRoger Jeffs Jun 29, 2017 to Sep 7, 201847
- Board memberH. Stewart Parker Jun 19, 2014 to now48
- Board memberSaira Ramasastry Jun 25, 2012 to Mar 1, 202249
- Board memberStephen George Dilly Apr 2, 2010 to Jun 3, 202050
- Board memberWilliam R. Ringo Apr 20, 2010 to Sep 22, 201751
- Board memberThomas G. Wiggans Jun 6, 2008 to Jun 3, 201152
- Board memberPaul B. Cleveland Nov 21, 2008 to Jun 15, 201653
- Board memberEdward O. Lanphier Ii. Jan 31, 2006 to Jan 13, 201715
- Board memberHenry Ward Wolff Jun 8, 2006 to Jun 11, 200754
- Board memberJohn William Larson Jun 8, 2006 to Jun 24, 201555
- Board memberMargaret Liu Jun 8, 2006 to Jun 6, 200856
- Board memberSteven J. Mento Jun 8, 2006 to Jun 12, 201857
- Board memberWilliam G. Gerber Jun 8, 2006 to Jun 3, 201058
- General counselScott B. Willoughby May 28, 2025 to now59
- General counselGary Loeb Aug 6, 2019 to Mar 25, 202160
- General counselHeather D. Turner Feb 16, 2018 to Feb 27, 201961
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Sangamo Therapeutics France S.A.S. France3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- SANGAMO BIOSCIENCES INCMay 19, 2000 to Jan 6, 20172
Timeline
- Sep 21, 20268-K Bankruptcy or receivership; Completed an acquisition or sale62
- Sep 8, 20268-K Bankruptcy or receivership; Completed an acquisition or sale; Regulation FD disclosure63
- Aug 28, 20268-K Entered a material agreement; Bankruptcy or receivership64
- Aug 13, 20268-K Other events65
- Aug 12, 20268-K Regulation FD disclosure66
- Jul 20, 20268-K Bankruptcy or receivership; Listing notice or transfer67
- Jul 1, 20268-K Change of auditor; Other events68
- Jun 23, 20268-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation69
- Jun 23, 20268-K Financial statements and exhibits70
- May 14, 20268-K Results of operations71
- Apr 29, 20268-K Listing notice or transfer72
- Mar 30, 20268-K Results of operations73
- Jun 6, 2016New chief executive Sandy Macrae becomes CEO14
- Jan 31, 2006New chief executive Edward O. Lanphier Ii. becomes CEO15
Calendar
When it reported results
- May 14, 2026Reported quarterly or annual results71
- Mar 30, 2026Reported quarterly or annual results73
- Feb 3, 2026Reported quarterly or annual results74
- Nov 6, 2025Reported quarterly or annual results75
- Aug 7, 2025Reported quarterly or annual results76
- Mar 17, 2025Reported quarterly or annual results77
- Nov 12, 2024Reported quarterly or annual results78
- Aug 6, 2024Reported quarterly or annual results79
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
339 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 72 major events, 192 insider forms, 23 large holders, 32 other. The latest 20:
- Oct 7, 202625-NSE EDGAR
- Sep 21, 20268-K EDGAR
- Sep 8, 20268-K EDGAR
- Aug 28, 20268-K EDGAR
- Aug 17, 2026NT 10-Q EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 20268-K EDGAR
- Aug 12, 20268-K EDGAR
- Jul 20, 20268-K EDGAR
- Jul 1, 20268-K EDGAR
- Jun 23, 20268-K/A EDGAR
- Jun 23, 20268-K EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 27, 20264 EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
- May 14, 202610-Q EDGAR
- May 14, 20268-K EDGAR
The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
16 open-market trades by officers, directors and large owners since October 2021: 2 buys and 14 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Davis Gregory DHead of Research & Technology | Sale | 69,827 | $0.25 | $17.5K | Form 4 |
| Apr 21, 2026 | Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER | Sale | 345,942 | $0.26 | $89.9K | Form 4 |
| Sep 26, 2023 | BIOGEN INC.10% owner | Sale | 6,000,000 | $0.50 | $3.0M | Form 4 |
| Aug 30, 2022 | BIOGEN INC.10% owner | Sale | 100,000 | $5.27 | $527.0K | Form 4 |
| Aug 29, 2022 | BIOGEN INC.10% owner | Sale | 400,000 | $5.33 | $2.1M | Form 4 |
| Jun 3, 2022 | Markels JohnDirector | Buy | 6,784 | $3.69 | $25.0K | Form 4 |
| Jun 1, 2022 | PARKER H STEWARTDirector | Buy | 5,000 | $3.60 | $18.0K | Form 4 |
| Dec 28, 2021 | BIOGEN INC.10% owner | Sale | 2,764 | $8.51 | $23.5K | Form 4 |
| Dec 27, 2021 | BIOGEN INC.10% owner | Sale | 600 | $8.56 | $5.1K | Form 4 |
| Dec 23, 2021 | BIOGEN INC.10% owner | Sale | 81,187 | $8.55 | $694.1K | Form 4 |
| Dec 9, 2021 | BIOGEN INC.10% owner | Sale | 23,660 | $8.56 | $202.5K | Form 4 |
| Dec 8, 2021 | BIOGEN INC.10% owner | Sale | 75,814 | $8.64 | $655.0K | Form 4 |
| Dec 7, 2021 | BIOGEN INC.10% owner | Sale | 52,178 | $8.52 | $444.6K | Form 4 |
| Dec 2, 2021 | Biogen MA Inc.10% owner | Sale | 1,874 | $8.51 | $15.9K | Form 4 |
| Dec 1, 2021 | Biogen MA Inc.10% owner | Sale | 730 | $8.52 | $6.2K | Form 4 |
| Nov 26, 2021 | Biogen MA Inc.10% owner | Sale | 28,884 | $8.60 | $248.4K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 14, 202680
- WASATCH ADVISORS LPSCHEDULE 13G/A, 8 filings Feb 11, 2022 to Nov 12, 202581
- VANGUARD GROUP INCSC 13G/A, 5 filings Feb 10, 2022 to Nov 12, 202482
- BiogenSC 13G/A, 2 filings Feb 12, 2024 to Aug 16, 202483
- BlackRockSC 13G/A, 4 filings Feb 1, 2022 to Jul 8, 202484
- State Street CorporationSC 13G/A, 2 filings Feb 7, 2023 to Jan 22, 202485
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2024 | Alexander D. Macrae | $716.4K | $2.5M86 | |
| 2024 | Prathyusha Duraibabu | 46 | $484.0K | $1.2M86 |
| 2024 | Scott B. Willoughby | 50 | $457.8K | $1.1M86 |
| 2024 | Nathalie Dubois-Stringfellow | $453.6K | $1.1M86 | |
| 2023 | Chief Executive Officer | $716.4K | $2.4M86 | |
| 2023 | Chief Financial Officer | $484.0K | $1.1M86 | |
| 2023 | Chief Development Officer | $453.6K | $1.0M86 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Nomura Asset Management International Inc. | 400,000 | $22.0K | 0.0% | No change |
| Simplex Trading, LLC | 76,500 | $4.1K | 0.0% | New |
| Axiom Investment Management LLC | 25,375 | $1.4K | 0.0% | No change |
| Heritage Investment Group, Inc. | 10,000 | $539 | 0.0% | New |
| Flow Traders U.s. LLC | 21,532 | $1 | 0.0% | +34 |
| Barclays PLC | 1 | $0 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How SANGAMO THERAPEUTICS, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSANGAMO THERAPEUTICS, INC1
- CIK0001001233
- Employer ID (EIN)68-03595564
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address501 Canal Blvd., Richmond, CA 940841
- Phone51097060001
- Shares outstanding414,288,847 as of May 11, 202612
- Public float$152.7M as of Jun 30, 20254
- AuditorErnst & Young LLP, San Mateo, California PCAOB ID 42; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceFeb 11, 20001
- Filings1,613 in all: 4 (830), 8-K (263), SC 13G/A (80), 10-Q (79), 3 (47), CT ORDER (33), 424B5 (27), SC 13G (27)1
All 44 form types
10-K (25), DEF 14A (25), 4/A (17), S-8 (17), 5 (15), DEFA14A (12), EFFECT (10), 8-K/A (9), CORRESP (9), UPLOAD (9), S-3 (8), ARS (7), S-1/A (6), S-8 POS (6), SC 13D/A (6), 10-K/A (5), POS AM (5), PRE 14A (5), S-3/A (4), SCHEDULE 13G/A (4), DEFR14A (3), S-3ASR (3), 144 (2), FWP (2), POSASR (2), 10-K405 (1), 10-Q/A (1), 25-NSE (1), 3/A (1), 424B3 (1), 8-A12G (1), NT 10-Q (1), RW (1), S-1 (1), SC 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 30, 2026
Quarterly report (10-Q) May 14, 2026
Proxy statement (DEF 14A) Apr 30, 2025
Latest 8-K (8-K) Sep 21, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.01 per share | SGMO | Nasdaq |
From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
The risks SANGAMO THERAPEUTICS, INC names in Item 1A of its 10-K filed Mar 30, 2026: 58 risks under these headings, as written.4
- Risks Relating to our Finances
- We have historically incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable.
- If we seek to reorganize under the U.S. Bankruptcy Code, our future operations are uncertain, and such reorganization could be unsuccessful and/or result in no recovery for holders of our common stock. If we are unable to successfully reorganize, we may be forced to pursue a liquidation of some or all of our assets.
- We have recorded significant impairment of our long-lived assets, and may be required to record significant additional charges if our long-lived assets become further impaired in the future.
- Our ability to use net operating losses to offset future taxable income may be subject to limitations.
- Risks Relating to Research, Development, Regulatory Approval and Commercialization of Our Product Candidates and Technologies
- Failure to successfully obtain regulatory approval for our Fabry companion diagnostic could prevent approval of our BLA and harm our commercial prospects.
- We are a biotechnology company with no approved products or product revenues. Our success depends substantially on results of preclinical studies and clinical trials demonstrating safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.
- Conducting clinical trials and obtaining regulatory approvals is complex and exposes our business to numerous risks, including potential unexpected costs and delays.
- Our core preclinical neurology programs, which are the current focus of our research and development efforts, are in the early stages. We may encounter difficulties in advancing product candidates from research programs to preclinical and clinical development and may fail to capitalize on product candidates with a greater commercial opportunity or for which there is a greater likelihood of success.
- Success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials may be materially different from final data.
- Our product candidates are subject to a lengthy and unpredictable regulatory approval process in each jurisdiction where approval is sought.
The other 47 risks
- We may not be able to identify, qualify and enroll sufficient patients for our clinical trials or complete our clinical trials in a timely manner, which could delay or prevent us from proceeding with the development of our product candidates.
- Special regulatory designations, such as RMAT, orphan drug designations, fast track designation, or PRIME may not be available for our product candidates or may not lead to a faster development or regulatory review or approval process.
- Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the approved indications or commercial potential, or result in significant negative consequences following any potential marketing approval.
- Even if our product development efforts are successful and even if the requisite regulatory approvals are obtained, our products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.
- Even if we are able to commercialize any approved products, such products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize them, which could harm our business.
- Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.
- Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.
- Our employees or contractors may engage in misconduct or other improper activities, including noncompliance with research, development, manufacturing or regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
- We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on other programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
- ZF technology is novel and has never been used to develop any approved, commercially viable therapeutic products.
- International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
- Disruptions at the FDA, including due to a reduction in workforce and/or inadequate funding, could prevent the FDA from performing normal functions on which our business relies, which could negatively impact our business. In addition, changes in FDA policies or regulations, as a result of the foregoing disruptions or otherwise, could adversely impact the development of our product candidates and, ultimately, our ability to receive approval for and commercialize our product candidates.
- Risks Relating to Manufacturing
- The transition of our manufacturing processes to third parties is a complex process, and there can be no assurance that third parties will be able to continue to manufacture our product candidates as intended and without delays.
- The manufacture, storage and transport of our product candidates is complex, expensive, highly regulated and risky, which could hamper their commercial viability.
- If we use chemical, biological or hazardous materials in a manner that causes injury or violates laws, we may be liable for damages.
- We are reliant on third parties for the manufacture of our product candidates for preclinical and clinical development. If one of our third-party manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers or manufacturers.
- We and third parties on which we rely may be adversely affected by natural disasters and catastrophic or other events outside of our control, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or event.
- Risks Relating to our Industry
- Our product candidates are based on novel genomic medicine technologies, which makes it difficult to predict the timing and costs of development and of subsequently obtaining regulatory approval.
- Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.
- Negative public opinion and increased regulatory scrutiny of genomic medicines may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
- Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse, privacy, data security and other healthcare laws and regulations. If we fail to comply with such regulations, we could face regulatory investigations or actions, litigation (including class claims) and mass
- arbitration demands, and substantial fines and penalties, and our business, reputation, results of operations, financial condition and prospects could be adversely affected.
- Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
- Unfavorable global economic conditions could have a negative impact on our operations, which could materially and adversely affect our ability to continue to operate as a going concern and otherwise have a material adverse effect on our business, financial condition, results of operations, prospects and market price of our common stock.
- Risks Relating to our Reliance on Third Parties
- If conflicts arise with our contractors, collaborators or other business partners, these conflicts may limit our ability to implement our strategies and may harm our business and prospects.
- Our collaborators control certain aspects of our product development efforts, including clinical trials and regulatory submissions, which could result in unanticipated delays and other obstacles in the commercialization of our product candidates.
- Our collaborators licensing our ZF technologies or AAV capsid technologies may decide to adopt alternative technologies or products or may be unable or unwilling to develop commercially viable products with our ZF technologies or AAV capsid technologies, which would negatively impact our revenues and our strategy to develop product candidates using ZF technologies or AAV capsid technologies.
- Our ability to continue funding our operations, advance development of our product candidates and ultimately commercialize our technologies depends on our ability to secure collaboration partners for our programs. If we are not able to find collaborators, or if our collaborators do not diligently pursue product development efforts, we will not be able to secure sufficient capital to continue to operate as a going concern.
- Risks Relating to our Intellectual Property
- Because it is difficult, time consuming and costly to obtain, maintain and enforce patent protections for our technologies and product candidates, and because third parties may have made inventions that are similar to ours, we may not be able to secure optimal patent protections of our technologies and product candidates.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time and may vary based on jurisdiction.
- If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be adversely affected, and our business would be harmed.
- We may not be successful in obtaining or maintaining necessary rights to product components, platforms and processes for our development pipeline through acquisitions and in-licenses.
- If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
- We may be involved in patent or intellectual property lawsuits or similar disputes involving patents under our control or patents of third parties claiming infringement, which lawsuits could be expensive, time-consuming and impair or prevent development and commercialization activities.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
- We may be unable to license gene transfer technologies that we may need to commercialize our ZF technology and potential products, if approved.
- We may not be able to protect our intellectual property rights throughout the world.
- We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- Risks Relating to our Business Operations
- If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm and other adverse consequences.
- We have business operations in the United Kingdom, which exposes us to additional costs and risks.
- We have experienced and may continue to experience difficulties in hiring, integrating and retaining qualified skilled employees.
- Risks Relating to our Common Stock and Corporate Organization
- Our stock price has been volatile and will likely continue to be volatile, which could result in substantial losses for investors and potentially class action securities litigation against us, and could be influenced by public perception of genomic medicines and the biotechnology sector.
- Actual or potential sales of significant amounts of shares of our common stock into the market could cause the market price of our common stock to fall or prevent it from increasing for numerous reasons.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
- Anti-takeover provisions in our certificate of incorporation, Delaware law and our bylaws could make an acquisition of our company more difficult and could prevent attempts by our stockholders to remove or replace current management.
- Our amended and restated bylaws designate exclusive forums for the adjudication of certain disputes, which could limit our stockholders’ ability to bring claims in a judicial forum it finds favorable for disputes with us or our directors, officers, or employees.
Legal proceedings
We are not a party to any material pending legal proceeding. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARKathy Yi, Chief financial officer
- 19
- 20
- 21
- 22SEC EDGARAmy Pooler, VP, Head of Research
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32SEC EDGAREdward R. Conner, Senior VP & CMO
- 33
- 34
- 35
- 36
- 37
- 38
- 39SEC EDGARCourtney Beers, Board member
- 40SEC EDGARMargaret A. Horn, Board member
- 41SEC EDGARJohn Markels, Board member
- 42SEC EDGARKenneth Hillan, Board member
- 43SEC EDGARJames R. Meyers, Board member
- 44SEC EDGARSandy Macrae, Board member
- 45SEC EDGARKaren L. Smith, Board member
- 46SEC EDGARJoseph S. Zakrzewski, Board member
- 47SEC EDGARRoger Jeffs, Board member
- 48SEC EDGARH. Stewart Parker, Board member
- 49SEC EDGARSaira Ramasastry, Board member
- 50SEC EDGARStephen George Dilly, Board member
- 51SEC EDGARWilliam R. Ringo, Board member
- 52SEC EDGARThomas G. Wiggans, Board member
- 53SEC EDGARPaul B. Cleveland, Board member
- 54SEC EDGARHenry Ward Wolff, Board member
- 55SEC EDGARJohn William Larson, Board member
- 56SEC EDGARMargaret Liu, Board member
- 57SEC EDGARSteven J. Mento, Board member
- 58SEC EDGARWilliam G. Gerber, Board member
- 59SEC EDGARScott B. Willoughby, General counsel
- 60SEC EDGARGary Loeb, General counsel
- 61SEC EDGARHeather D. Turner, General counsel
- 62
- 63
- 64
- 65SEC EDGAROther events
- 66SEC EDGARRegulation FD disclosure
- 67
- 68SEC EDGARChange of auditor; Other events
- 69
- 70SEC EDGARFinancial statements and exhibits
- 71SEC EDGARResults of operations
- 72SEC EDGARListing notice or transfer
- 73SEC EDGARResults of operations
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86